Journal of Neurochemistry · 1989 · 67 citations · 22 references
MedicineNeurosciencePharmacologyMolecular PharmacologyNeurochemistryNeuropharmacologyDrug ReceptorsDrug-receptor InteractionsLigand BindingNeurotransmissionReceptor PharmacologySerotonergic Pharmacology5-Hydroxytryptamine 3 Receptor Antagonists5-Hydroxytryptamine Receptor PharmacologyCns PharmacodynamicsDrug Receptor PharmacologyMonoamine PharmacologyMonoamine ReceptorsPharmacological PotencyReceptor Binding Profiles
[3H]Quipazine was used to label binding sites in rat brain membranes that display characteristics of a 5-hydroxytryptamine3 (5-HT3) receptor. The radioligand binds with high affinity (KD, 1.2 +/- 0.1 nM) to a saturable population of sites (Bmax, 3.0 +/- 0.4 pmol/g of tissue) that are differentially located in the brain. Specific [3H]quipazine binding is not affected by guanine or adenine nucleotides. ICS 205-930, BRL 43964, Lilly 278584, and zacopride display less than nanomolar affinity for these sites whereas MDL 72222 is approximately one order of magnitude less potent. The pharmacological profile of the binding site is in excellent agreement with that of 5-HT3 receptors characterized in peripheral physiological models. We conclude that [3H]quipazine labels a 5-HT3 receptor in the rat CNS.
22
Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine
Philip Bradley, G. Engel, W. Feniuk et al. · Neuropharmacology · 1986 · 1.3K citations
Medicine, Neuroscience, Pharmacology +12
Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs
B. P. Richardson, G. Engel, P. Donatsch et al. · Nature · 1985 · 842 citations
The pharmacology and function of 5-HT3receptors
B. P. Richardson, G. Engel · Trends in Neurosciences · 1986 · 385 citations
Medicine, Neuroscience, Pharmacology +10